Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
Rhea-AI Summary
Kala Bio (KALA) signed a definitive exclusive U.S. distribution and reseller agreement with Virotek for an ophthalmology genomic testing and screening program, effective September 4, 2026, with an initial one-year term and exclusivity tied to commercial milestones.
Under the Agreement, Kala has exclusive rights to market, promote, distribute, and resell Virotek’s ophthalmology genomic program across the United States, while Virotek continues to operate laboratory infrastructure, kit supply, specimen processing, and clinical reporting, and to train Kala’s channel partners. The parties agreed to a profit-sharing structure that begins once Virotek has recovered its program costs, although further commercial terms are not disclosed.
The Agreement also gives Kala a right of first refusal over certain future ophthalmology products and services and establishes a framework to potentially add oncology, preventive-health, telehealth, and white-label distribution verticals by mutual agreement. Kala ties this deal to its staged, capital-efficient partnership strategy and notes that it has not issued any revenue projections and that results are not assured.
Positive
- Exclusive U.S. distribution rights for ophthalmology genomic testing program for an initial one-year term, contingent on commercial milestones
- Profit-sharing structure established, effective after Virotek recovers its program costs
- Right of first refusal for certain future ophthalmology products and services from Virotek
- Framework for added verticals including oncology, preventive-health testing, telehealth, and white-label channels
- Access to a commercially active program in a U.S. genetic testing market cited at approximately $5.7 billion in 2025 and $6.9 billion projected for 2026
Negative
- Exclusivity limited to an initial one-year term, with continuation dependent on Kala meeting agreed commercial milestones
- Profit share begins only after cost recovery, as Virotek must first recover its program costs
- No revenue projections disclosed and Kala explicitly states there is no assurance this transaction will produce anticipated results
- Expansion into additional verticals is conditional on future mutual agreement, with no committed timelines or terms
Market Reaction – KALA
Following this news, KALA has gained 0.04%, reflecting a mild positive market reaction. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.52. Trading volume is exceptionally heavy at 143.3x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Partnership Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Sep 01 | Partnership LOI | Positive | -20.9% | LOI outlined exclusive U.S. distribution rights but remained subject to negotiation and approvals |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The prior partnership announcement was positive in substance but coincided with a -20.89% 24-hour reaction.
Key Terms
genetic testing medical
genomic testing medical
profit-sharing structure financial
right of first refusal regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program
ARLINGTON, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek") today announced that they have finalized a definitive exclusive distribution and reseller agreement (the "Agreement") and related quality, brand, and data protection agreements. Under the Agreement, Kala will be the exclusive distributor and reseller in the United States for an initial one-year term, with continued exclusivity contingent on Kala achieving agreed commercial milestones for Virotek's ophthalmology genetic testing and screening program. The Agreement follows the non-binding letter of intent announced by the companies on September 1, 2026, and takes effect on September 4, 2026.
Under the Agreement, Kala holds the exclusive right to market, promote, distribute, and resell Virotek's ophthalmology genomic program throughout the United States for an initial one-year term, with exclusivity contingent on Kala achieving agreed commercial milestones. Virotek continues to operate the program's infrastructure, kit supply, specimen processing, and clinical reporting, and will provide training and program materials to Kala's channel partners. The companies have agreed to a profit-sharing structure for the program, effective once Virotek recovers its program costs. This release does not set out additional commercial and financial terms of the Agreement.
The Agreement also includes a right of first refusal in favour of Kala for certain ophthalmology products and services that Virotek may propose to sell or license to a third party. It also establishes a framework under which the companies may, by mutual agreement, activate additional clinical verticals over time, including oncology, a preventive-health testing franchise, telehealth, and white-label distribution channels.
According to third-party market research, the U.S. genetic testing market was valued at approximately
The Agreement reflects Kala’s capital allocation strategy of building operating scale through a series of staged, capital-efficient partnerships, growth initiatives, and acquisition opportunities. Kala’s approach is to pursue opportunities it believes can contribute to its operating base and be accretive over time, while preserving flexibility to evaluate additional opportunities as they arise. Kala believes that a staged approach allows the company to manage execution risk, deploy capital selectively against demonstrated milestones, and build a platform intended to support long-term growth. There can be no assurance that any particular transaction, including this one, will produce the results Kala anticipates.
Over time, the companies may explore U.S.-based laboratory capacity for the program, in addition to Virotek's existing accredited laboratory operations, subject to further agreement on scope, cost, and timing.
"This agreement grants Kala exclusive U.S. rights to a commercially active genomic testing program in ophthalmology, a field in which Kala has operated for more than a decade. Our strategy is to build operating scale through disciplined, staged transactions. This is a step we can take now while we continue to evaluate other opportunities. We are moving into execution with the Virotek team," said Avi Minkowitz, Chief Executive Officer of Kala.
"Signing this agreement moves us from intent to execution. Kala's commercial reach and public-company platform provide our ophthalmology program with a fast path to eye care practices, telehealth channels, and patients across the United States. We're already working together on the roadmap to expand into oncology and preventive health," said Dr. Saeid Babaei, Chairman and Chief Executive Officer of Virotek.
About Kala Bio, Inc. (NASDAQ: KALA)
KALA BIO, Inc. is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company's dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business designed to deploy secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments.
Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. The Company's focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector.
Kala believes the future of biomedical innovation is in agentic systems.
For more information, visit www.kalarx.com and Researgency.ai
About Virotek
Virotek is a Wyoming-based corporation offering precision health and clinical genomics products and services to healthcare providers and organizations that span the full continuum of care — from preventive risk assessment, through early cancer detection, to personalized treatment guidance — delivered from a single, integrated platform. For more information, visit Virotek.io.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's strategic initiative to build an AI infrastructure platform for the biotechnology industry; plans to develop and deploy the Researgency AI platform both internally and to external clients; expectations regarding the potential benefits of AI-driven analytical tools; plans to reassess historical datasets and identify new therapeutic indications; expectations regarding the AI drug discovery market and industry trends; expectations regarding the Company's ability to generate recurring platform revenue; plans regarding potential partnerships, client deployments, or technology licensing opportunities; expectations regarding the Company's competitive position and the differentiation of its on-premises deployment model; the potential exercise of development continuation or renewal options under the Agreement; and other statements that are not historical facts. It also includes statements regarding the proposed distribution partnership with Virotek, including the negotiation and execution of definitive agreements and the anticipated benefits and timing thereof.
The Company used words like "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions to identify these forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements to be materially different from those expressed or implied by such statements. Important factors that could cause such differences include, but are not limited to: risks that AI technologies may not produce expected results in drug discovery or development; risks related to the development, deployment, and performance of the Researgency platform; risks that the Company may not successfully attract or retain external platform clients; risks that the platform-as-a-service business model may not generate anticipated revenues; risks that the Company's product candidates may not be successfully developed or commercialized; risks related to the Company's limited cash resources and ability to continue as a going concern; risks that the third-party information contained herein was not accurate at the time it was published and/or does not accurately predict the future; risks related to the Company's ability to raise future capital and the possibility that market conditions may limit the Company's ability to raise capital on favorable terms; risks related to the Company's ability to regain compliance with Nasdaq listing requirements; competition from larger, better-resourced companies including major technology and pharmaceutical companies; dependence on key personnel and third-party technology providers; the accuracy of third-party market forecasts and projections cited herein; risks that the Company may elect not to expand or continue its deployment of the Researgency platform beyond the initial term; risks that Younet may not perform its obligations under the Agreement; and other risks detailed in the "Risk Factors" section of the Company's Annual Report on Form 10-K as they may be revised in the Company's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and other filings with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact:
Avi Minkowitz
Chief Executive Officer, KALA BIO, Inc.
am@kalarx.com
www.kalarx.com | www.Researgency.ai
Dr. Saeid Babaei
Chairman and Chief Executive Officer, Virotek Inc.
info@virotek.io
FAQ
What did Kala Bio (KALA) announce about its partnership with Virotek?
Kala Bio announced a definitive exclusive distribution and reseller agreement with Virotek for an ophthalmology genomic testing and screening program in the United States. The deal grants Kala exclusive rights to market, promote, distribute, and resell the program under a milestone-based structure.
What are the key terms of the Kala Bio (KALA) and Virotek distribution agreement?
The Agreement gives Kala exclusive U.S. rights to distribute and resell Virotek’s ophthalmology genomic program for an initial one-year term, with continued exclusivity contingent on achieving agreed commercial milestones. It also includes a profit-sharing structure that starts once Virotek recovers its program costs.
When does the Kala Bio (KALA) and Virotek exclusive distribution agreement take effect?
The exclusive distribution and reseller agreement between Kala Bio and Virotek takes effect on September 4, 2026. The initial term is one year, after which continued exclusivity depends on Kala meeting the commercial milestones defined in the Agreement.
What operational roles do Kala Bio (KALA) and Virotek have in the genetic testing partnership?
Kala is responsible for marketing, promoting, distributing, and reselling the ophthalmology genomic program in the U.S. Virotek continues to operate program infrastructure, kit supply, specimen processing, and clinical reporting, and will provide training and program materials to Kala’s channel partners.
Does Kala Bio (KALA) have rights to future products from Virotek under this agreement?
Yes. The Agreement includes a right of first refusal for Kala on certain ophthalmology products and services that Virotek may propose to sell or license to third parties. It also outlines a framework to potentially add new clinical verticals by mutual agreement.
How does this Virotek agreement fit Kala Bio’s (KALA) growth strategy?
Kala describes the Agreement as part of its capital allocation strategy to build operating scale through staged, capital-efficient partnerships, growth initiatives, and acquisitions. The company believes this approach allows selective capital deployment against milestones, while cautioning that no transaction’s results, including this one, are assured.